The Role of Inflammatory Biomarkers in the Pre-Biopsy Risk Stratification of Patients with Suspicious Mri Lesions of the Prostate: Where Should We Head?

References

1. Bergengren O. Pekala K.R. Matsoukas K. Fainberg J. Mungovan S.F. Bratt O. Bray F. Brawley O. Luckenbaugh A.N. Mucci L. Morgan T.M. Carlsson S.V. 2022 Update on Prostate Cancer Epidemiology and Risk Factors—A Systematic Review. Eur. Urol. 2023 84 2 191 206 10.1016/j.eururo.2023.04.021 37202314
   [Google Scholar]
2. Yin X. Xiao Y. Li F. Qi S. Yin Z. Gao J. Prognostic role of neutrophil-to-lymphocyte ratio in prostate cancer. Medicine (Baltimore) 2016 95 3 e2544 10.1097/MD.0000000000002544 26817900
   [Google Scholar]
3. Woodrum D.A. Kawashima A. Gorny K.R. Mynderse L.A. Targeted prostate biopsy and MR-guided therapy for prostate cancer. Abdom. Radiol. (N.Y.) 2016 41 5 877 888 10.1007/s00261‑016‑0681‑3 26907717
   [Google Scholar]
4. Rajwa P. Huebner N.A. Hostermann D.I. Grossmann N.C. Schuettfort V.M. Korn S. Quhal F. König F. Mostafaei H. Laukhtina E. Mori K. Motlagh R.S. Yanagisawa T. Aydh A. Bryniarski P. Pradere B. Paradysz A. Baltzer P.A. Grubmüller B. Shariat S.F. Evaluation of the Predictive Role of Blood-Based Biomarkers in the Context of Suspicious Prostate MRI in Patients Undergoing Prostate Biopsy. J. Pers. Med. 2021 11 11 1231 10.3390/jpm11111231 34834583
   [Google Scholar]
5. Cornford P van den Bergh RCN Briers E EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Eur. Urol. 2024 86 2 148 163 10.1016/j.eururo.2024.03.027
   [Google Scholar]
6. Giannakodimos I. Urinary miRNAs as Diagnostic Biomarkers for Prostatic Cancer: Current Dilemmas and Novel Potential Role for a Digital Rectal Examination. Curr. Med. Chem. 2022 29 25 4311 4313 10.2174/0929867329666220118101733 35040397
   [Google Scholar]
7. Ziogou A. Giannakodimos A. Giannakodimos I. The Role of Urinary miRNAs in the Diagnosis, Management and Follow- Up of Prostatic Cancer. MicroRNA 2023 12 2 83 86 10.2174/2211536612666230324102850 36999432
   [Google Scholar]
8. Giannakodimos I. Urinary miRNAs and Prostate Cancer: Is there a Crossover Point Eventually, and where should we Head? Curr. Med. Chem. 2024 31 41 6733 6734 10.2174/0109298673304111240325062717 38571346
   [Google Scholar]
9. Gholami N. Haghparast A. Alipourfard I. Nazari M. Prostate cancer in omics era. Cancer Cell Int. 2022 22 1 274 10.1186/s12935‑022‑02691‑y 36064406
   [Google Scholar]
10. Cornford P. van den Bergh R.C.N. Briers E. Van den Broeck T. Brunckhorst O. Darraugh J. Eberli D. De Meerleer G. De Santis M. Farolfi A. Gandaglia G. Gillessen S. Grivas N. Henry A.M. Lardas M. van Leenders G.J.L.H. Liew M. Linares Espinos E. Oldenburg J. van Oort I.M. Oprea-Lager D.E. Ploussard G. Roberts M.J. Rouvière O. Schoots I.G. Schouten N. Smith E.J. Stranne J. Wiegel T. Willemse P.P.M. Tilki D. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer—2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur. Urol. 2024 86 2 148 163 10.1016/j.eururo.2024.03.027 38614820
    [Google Scholar]
11. Wei J.T. Barocas D. Carlsson S. Coakley F. Eggener S. Etzioni R. Fine S.W. Han M. Kim S.K. Kirkby E. Konety B.R. Miner M. Moses K. Nissenberg M.G. Pinto P.A. Salami S.S. Souter L. Thompson I.M. Lin D.W. Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy. J. Urol. 2023 210 1 54 63 10.1097/JU.0000000000003492 37096575
    [Google Scholar]
12. Wang L. Li X. Liu M. Zhou H. Shao J. Association between monocyte-to-lymphocyte ratio and prostate cancer in the U.S. population: A population-based study. Front. Cell Dev. Biol. 2024 12 1372731 10.3389/fcell.2024.1372731 38645410
    [Google Scholar]
13. Kaynar M. Yildirim M.E. Gul M. Kilic O. Ceylan K. Goktas S. Benign prostatic hyperplasia and prostate cancer differentiation via platelet to lymphocyte ratio. Cancer Biomark. 2015 15 3 317 323 10.3233/CBM‑150458 25586096
    [Google Scholar]
14. Sun J. Zhang Z. OuYang J. A novel nomogram combined PIRADS v2 and neutrophil-to-lymphocyte ratio to predict the risk of clinically significant prostate cancer in men with PSA < 10 ng/ml at first biopsy. Urol. Oncol. 2020 38 5 401 409 10.1016/j.urolonc.2019.12.006 31870724
    [Google Scholar]